Loading organizations...
Seaport Therapeutics is a clinical-stage biopharmaceutical company developing novel neuropsychiatric medicines, focusing on antidepressants and anxiolytics. Its proprietary Glyph™ Technology Platform enhances drug delivery, ensuring oral bioavailability, bypassing first-pass metabolism, and reducing side effects. This approach advances compounds previously hindered by pharmacological constraints.
Founded by Daphne Zohar, CEO, and Steven M. Paul, M.D., Chairman, Seaport Therapeutics launched April 9, 2024. Their insight recognized many clinically validated neuropsychiatric mechanisms were underutilized due to delivery challenges. Ms. Zohar co-founded Karuna Therapeutics and PureTech Health; Dr. Paul led Karuna and Lilly Research Laboratories, advancing key CNS drugs.
Seaport Therapeutics targets patients with major depression, anxiety, and other neuropsychiatric conditions. The company’s mission is to deliver first-in-class treatments, addressing unmet medical needs. Leveraging its Glyph platform to unlock difficult therapies, Seaport aims to improve outcomes for millions.
Seaport Therapeutics has raised $345.0M across 3 funding rounds.
Seaport Therapeutics has raised $345.0M in total across 3 funding rounds.
Seaport Therapeutics has raised $345.0M in total across 3 funding rounds.
Seaport Therapeutics's investors include Advanced Research Projects Agency for Health, General Atlantic, venBio, ARCH Venture Partners, Foresite Capital, Goldman Sachs, Invus, Bharatt Chowrira, Sofinnova Ventures, Third Rock Ventures, T. Rowe Price Associates, Sofinnova Investments.
Seaport Therapeutics has raised $345.0M across 3 funding rounds. Most recently, it raised $15.0M Grant in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 4, 2026 | $15M Grant | Advanced Research Projects Agency For Health | — | Announced |
| Oct 1, 2024 | $230M Series B | General Atlantic | VenBio Partners, ARCH Venture Partners, Foresite Capital, Goldman Sachs, Invus, Bharatt Chowrira, Sofinnova Investments, Third Rock Ventures, T. Rowe Price Associates | Announced |
| Apr 1, 2024 | $100M Series A | ARCH Venture Partners, Sofinnova Investments | DeepWork Capital, General Atlantic, Mike Moradi, Eric Elenko, Third Rock Ventures | Announced |
Seaport Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing novel neuropsychiatric medicines for areas of high unmet patient needs, such as depression, anxiety, and schizophrenia.[1][2][4] It builds a pipeline of first- and best-in-class oral therapies powered by its proprietary Glyph technology platform, which enables oral bioavailability, bypasses first-pass metabolism, and reduces hepatotoxicity and other side effects for clinically validated mechanisms previously limited by delivery challenges.[1][2][4][6] The company serves patients with neuropsychiatric disorders, addressing problems like debilitating side effects of existing treatments by advancing safer, more effective options; it demonstrates growth momentum through recent presentations at investor conferences, investments from firms like General Atlantic in 2024, and a team with a track record of FDA-approved drugs like Cobenfy (formerly KarXT).[2][5][6]
Seaport Therapeutics was founded by Daphne Zohar, who serves as CEO and Board Member, building on her prior success at PureTech Health, where she co-founded entities including Karuna Therapeutics—acquired by Bristol Myers Squibb for $14 billion in 2024 after developing Cobenfy (KarXT), the first new schizophrenia drug class in over 50 years.[3][6] The idea emerged from Zohar's experience inventing and advancing neuropsychiatric medicines at PureTech, where her team achieved clinical success rates six times the industry average, including KarXT's three pivotal studies leading to FDA approval in September 2024.[3][6] Early traction stems from this proven strategy: leveraging clinically validated mechanisms held back by pharmacokinetic issues, now unlocked via the Glyph platform, with the company launching in 2024 amid strong investor backing like General Atlantic.[5][6]
Seaport rides the wave of innovation in neuropsychiatry, targeting a market plagued by inadequate treatments—e.g., schizophrenia's first new mechanism in 50+ years via KarXT, now commercialized as Cobenfy, highlighting demand for side-effect-free options amid rising mental health crises.[6] Timing is ideal post-2024 Karuna acquisition and FDA approval, fueling investor confidence in de-risked pipelines; market forces like aging populations, post-pandemic anxiety/depression surges, and biopharma's shift to oral small molecules favor Seaport's platform.[2][3][6] It influences the ecosystem by validating PureTech-style "invention labs," accelerating clinically proven ideas via tech platforms, and setting benchmarks for biotech efficiency in high-unmet-need areas.[3]
Seaport is poised for pipeline milestones, with Glyph-enabled candidates advancing into clinical trials for depression and anxiety, potentially mirroring KarXT's path to blockbuster status and partnerships/acquisitions.[2][4][6] Trends like AI-driven drug design and oral CNS breakthroughs will amplify its edge, while mental health funding booms could drive rapid scaling. Its influence may evolve from niche innovator to category leader, much like Karuna, tying back to its core strength: turning validated science into patient wins via smart tech.
